RxDoctor Payments Data

Nilay Kumar

Gastroenterology · Milwaukee, WINPI 1427123702

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,500 of the $5,555 with a category attached, or 81.0%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 81.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $3,117 and has fallen 96.4% since, to $111 in 2025.

$5,555in general payments, 2019–2025

Across 16 payments — averaging $347.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • Cook Medical LLC$460
  • AbbVie$326
  • Boston Scientific$144
  • E.r. Squibb & Sons, L.L.C.$125
$11,333in research payments, 2019–2025

Across 6 payments — averaging $1888.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$11K

What the payments were for

  • Speaking & faculty fees$4,50081%
  • Food & beverage$1,05519%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,555 in reported general payments places this provider in the 85th percentile of 285 gastroenterology providers in Wisconsin.

See all gastroenterology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$149,561
Medicare patients
464
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates227$14,043
LinzessLinaclotide14$10,834
Mesalamine16$5,766
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg256$4,902
Pantoprazole Sodium312$4,472
Omeprazole118$2,015
CholestyramineCholestyramine (With Sugar)14$1,089
Budesonide DrBudesonide12$871
Sucralfate14$657
Famotidine22$525
Prednisone11$376
Hydrocortisone17$203
Dicyclomine Hcl21$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$326$10,83414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 gastroenterology providers in Wisconsin.

Other gastroenterology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →